Very low pacemaker rate following ACURATE neo transcatheter heart valve implantation
Why the study?
Does transfemoral TAVI with the ACURATE neo valve and careful sizing strategies reduce the occurrence of new conduction disorders and the need for permanent pacemakers?
Population
175 patients undergoing transfemoral transcatheter aortic valve implantation, mean age 83±6 years, 58%…
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change valve selection; extends observational data on conduction safety pending randomized confirmation.
Structured PICO
Does transfemoral TAVI with the ACURATE neo valve and careful sizing strategies reduce the occurrence of new conduction disorders and the need for permanent pacemakers?
P
Population
175 patients undergoing transfemoral transcatheter aortic valve implantation (TAVI), mean age 83±6 years, 58% female, across three centres in Europe.
I
Intervention
Transfemoral TAVI with the Boston Scientific ACURATE neo prosthesis, with prosthesis size selection based on perimeter-derived annular diameter, predilatation in all patients, and post-dilatation in 26.3%.
O
Outcome
Occurrence of new conduction disorders and the need for permanent pacemakerssafety
Transfemoral TAVI with the ACURATE neo valve, using careful sizing based on perimeter-derived annular diameter, is associated with a very low rate of new permanent pacemaker implantation (2.3%) without increasing paravalvular regurgitation.
Cite This Study
Toggweiler et al. (2017) studied this question.